The past decade has brought forth some major transformations in IBD treatment as well as the medications that are commonly recommended to alleviate debilitating IBD conditions and acute gastrointestinal inflammation. The mainstay of inflammatory bowel disease treatments involve several chemically-derived medicines such as steroids and immunosuppressive drugs. However, the FDA approval of infliximab, a genetically engineered drug for IBD treatment led to a new era in IBD treatment. Biologics is recommended only when immunosuppressive drugs, antibiotics, and anti-inflammatory drugs fail to help inflammatory bowel disease patients achieve and maintain deep remission or the symptom-free phase which is indispensable to regain the overall health and wellness. TNF-alpha or the GI inflammation causing agent is created by activated macrophages and T lymphocytes. Infliximab, adalimumab, certolizumab and other monoclonal antibodies offer a distinct advantage that augments biologics IBD treatment as well as the overall healing process. By inducing targeted actions that help heal the affected area of the body without supressing the immune system, biologics lessen the vulnerability of diseases and infections that are triggered by a weaker and improperly functioning immune system. Biologics therapies targeted to combat defective and deficient proteins and enzymes that induce GI inflammation.

Intravenous biologic medications:

The first FDA approved biologic drug, infliximab (Remicade) is recommended for both Crohn’s disease and ulcerative colitis treatments. A chimeric monoclonal antibody, infliximab is hybrid of 75 percent human and 25 percent mouse proteins. By preventing the activities of inflammation-causing proteins, and TNF alpha in particular infliximab successfully outruns chemically-derived drugs, through intravenous infusion which extend to about three hours. Infliximab therapy is an eight week process.

Natalizumab induces and maintains remission in adult IBD patients who suffer from moderate to severe disease conditions. Natalizumab is an antibody that successfully inhibits the inflammation causing activities of WBC. A four weeks therapy to curb IBDs, every dose of Natalizumab is carefully infused into the vein.

Vedolizumab, an integrin receptor antagonist, is recommended for patients who suffer from moderate to severe IBD conditions. Vedolizumab is infused intravenously.

More information can be obtained on https://www.gutpeople.net a bespoke social networking website, developed solely for gastroenterologists around the world. GI health care experts who specialize in GI disorders can register with The Gut People and start interacting with top GI experts around the world, on various commonly found gastrointestinal disorders like inflammatory bowel disease and intestinal tuberculosis. The Gut People is also equipped with unique functionalities that help download informative documents on gastrointestinal disorders, as well as their comprehensive diagnosis steps and advance treatment methods.

 For more info: https://www.gutpeople.net